Search

everythinglearnresearchcommunity

for

Search:↓

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.

A 19-year-old experiencing diffuse thinning on the top of the head has seen some improvement with ketoconazole but is considering starting finasteride. They are seeking advice on whether to begin this treatment as they approach their 20th birthday.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

A female user is experiencing heavy hair shedding and receding temples, possibly due to low ferritin levels. She is using oral minoxidil, iron supplements, and ketoconazole shampoo, and is hesitant to start spironolactone.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

John Cazale's hairline showed strong recession at the temples but maintained solid volume and density, sparking discussion on different hair loss patterns and the importance of overall hair density. Treatments like Minoxidil and Spironolactone were mentioned as potential factors in maintaining hair, though genetics and styling were also considered significant.

User experienced hair thinning due to high cortisol and thyroid issues, along with insulin resistance. They are taking magnesium, zinc, vitamin D, calcium, and selenium as supplements.

A 25-year-old male shared his one-year hair loss progress using oral finasteride, oral minoxidil, and weekly ketoconazole, noting stabilized hair loss but no recent improvement. He is considering a hair transplant and possibly PRP sessions, while planning to continue medication.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A 30-year-old man with diffuse hair thinning shared his hair regrowth regimen, which includes increasing Vitamin D intake, taking oral castor oil, using a dermapen, and various supplements like Glycine, K2, Vitamin E, Vitamin C, Aspirin, Sodium Bicarbonate, and a multivitamin. He also mentioned inconsistent use of Minoxidil, Peppermint Oil, Zix, and topical Castor Oil, and negative side effects from Finasteride, RU58841, and Nizoral.

Finasteride and oral minoxidil effectively maintain a youthful appearance and full head of hair, despite genetic predispositions to balding. The discussion also considers the impact of DHT blockers on masculinity and aging, with lifestyle choices like sunscreen use and a vegetarian diet mentioned.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

A user experiencing diffuse thinning since age 18 describes their hair as unhealthy, dry, thin, and hard, with texture changes cycling between good and bad every few weeks. They are not on any medication, only taking vitamins and supplements.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user has been using finasteride, dutasteride, pyrithione zinc, and oral minoxidil to treat hair loss and has seen an increase in fine hairs on the hairline but overall thinning on the top. They are considering adding zinc and Vitamin K to their regimen and are already taking hair multivitamins with collagen.

The conversation discusses skepticism about a new hair loss treatment called project K, which claims to replicate a chemical from UCLA research but is suspected to be a scam. The original poster plans to continue using oral minoxidil, finasteride, and dutasteride, along with microneedling, for hair regrowth.

Skin, Hair, and Nails by Pharmekal was withdrawn from the market. Users discuss alternative supplements and treatments like Minoxidil, finasteride, and RU58841.

Lysine supplementation at 2 grams daily reduced hair shedding by 25% and made hair strands thicker. The user highly recommends lysine for hair health.

Pyrilutamide (KX-826) is being discussed as a potential hair loss treatment, with some users reporting no regrowth after three months. It may prevent further hair loss but might not promote regrowth unless combined with Minoxidil.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.

The conversation discusses concerns that Minoxidil may cause skin aging, like collagen depletion and puffier faces. Some users suggest that a good skincare routine or collagen supplements might prevent these effects.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user is using 1% ketoconazole shampoo, 5% minoxidil foam, and a multi-peptide hair serum to address hair loss, aiming to improve from Norwood 5 to Norwood 3. They are considering adding topical finasteride if current treatments show progress and plan to use cosmetic products like fibers and DermMatch for appearance enhancement.

KX-826 is discussed as a hair loss treatment, with comparisons to finasteride. It is noted to be more expensive, harder to source, and generally used for stabilization rather than growth.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

A user is experiencing significant hair loss and stress, seeking advice on treatments. They are using Pura d'or shampoo and conditioner, biotin, and considering other options but are hesitant about treatments like Minoxidil due to the need for continuous use.